Introduction {#sec1}
============

Knowledge on transcriptional regulators of pancreatic development and beta cell differentiation is essential for the development of beta cell replacement therapies for diabetes ([@bib23; @bib58]). While major work has been undertaken in mice, the extent to which murine pancreatic development is a good model for man is not fully understood.

Finding inactivating mutations in patients with diabetes can establish the role of a gene in human pancreatic development and function. Comparing the human phenotype with mouse models for the same gene is important, as it validates that the gene function is similar in man and mouse. Concordant phenotypes between mouse models with biallelic gene inactivation and humans with biallelic mutations suggest similar function of the gene product in rodents and man. For example, biallelic *GCK* mutations in humans cause permanent neonatal diabetes (PNDM), and mice lacking both copies of the gene have severe hyperglycemia at birth ([@bib32; @bib51]). Both patients with recessive *EIF2AK3* mutations and the *Perk* null mouse (*Eif2ak3*^−/−^) develop diabetes due to destruction of beta cells as a result of endoplasmic reticulum stress ([@bib9; @bib14; @bib57])

The correlation in phenotype between knockout mice and humans with recessive mutations is not always evident. Biallelic loss-of-function *ABCC8* mutations are the most common known cause of hyperinsulinemic hypoglycemia in humans, whereas *ABCC8* null mice maintain euglycemia ([@bib45; @bib53]). GLUT2 has been shown to be the primary glucose transporter and sensor in rodent pancreatic islets, whereas studies in humans have suggested that GLUT1 plays an important role in facilitating glucose entry into the developing beta cell ([@bib8; @bib26]). An example of a difference at the level of the gene structure is the insulin gene: in humans preproinsulin is encoded by a single gene (*INS*), while in mice two functional copies of the gene exist (*Ins1* and *Ins2*).

Studies investigating transcriptional regulation of beta cell development in mice have, however, been successful in identifying pancreatic transcription factor genes important for human pancreatic development. Much of the mouse work has involved the complete or targeted (conditional) knockout of a gene followed by detailed phenotypic studies during embryonic development and, when viable, in the resulting live offspring. To date, mutations in eight different pancreatic transcription factor genes (*PDX1*, *PTF1A*, *GLIS3*, *PAX6*, *RFX6*, *NEUROD1*, *NEUROG3*, *GATA6*) have been identified in patients with neonatal diabetes ([@bib24; @bib39; @bib40; @bib42; @bib43; @bib46; @bib47; @bib48]). For some transcription factor genes the genetic etiology in the patients was initially recognized from the similarity to the mouse phenotype ([@bib39; @bib48]). Mutations causing a pancreatic/diabetes phenotype have not been found in man for many pancreatic transcription factors important for rodent pancreatic development, but there have been no large, systematic studies of these genes in appropriate patients to date.

The aim of our study was to perform a comprehensive search for recessive mutations in genes encoding transcription factors known to be critical for pancreatic development in mice in a large collection of PNDM patients born to consanguineous parents. Patients with consanguineous parents were chosen, as the likelihood of a recessive cause of their PNDM is greatly increased ([@bib38]), and all mouse models of transcription factors influencing pancreatic development involve biallelic inactivation. We tested for mutations in homozygous regions encompassing known transcription factor genes independently of the clinical features to avoid the possible bias introduced when clinical features guide candidate gene testing.

Results and Discussion {#sec2}
======================

We studied 147 patients from consanguineous pedigrees. Mutations in non-transcription factor genes were identified in 110 probands (75%) ([Table 1](#tbl1){ref-type="table"}, [Figure S1](#app2){ref-type="sec"}, and [Table S1](#app2){ref-type="sec"}). Systematic investigation of 29 transcription factor genes important for murine pancreatic development identified homozygous mutations in 7 genes in 12 patients from 11 families (30% of the undiagnosed probands or 7.5% of the entire cohort) ([Table 1](#tbl1){ref-type="table"}). Overall, 106 out of 121 (88%) patients with a known genetic etiology had homozygous mutations, confirming that neonatal diabetes in the offspring of consanguineous families is usually recessive.

Homozygous Mutations in *NKX2-2* Cause Neonatal Diabetes {#sec2.1}
--------------------------------------------------------

Homozygous *NKX2-2* nonsense or frameshift mutations were identified in three patients from two families ([Table 2](#tbl2){ref-type="table"}). These mutations are highly likely to be pathogenic, as they are null mutations. Cosegregation studies were consistent with recessive inheritance ([Figure 1](#fig1){ref-type="fig"}A). No heterozygous or homozygous truncating mutations have been reported in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>). All three patients have severe defects in insulin secretion, as shown by intrauterine growth retardation (IUGR) and presentation of diabetes at an early age without features of pancreatic exocrine dysfunction ([Table 2](#tbl2){ref-type="table"}). This is very similar to mice that are homozygous for a targeted disruption of *Nkx2-2* and die shortly after birth with severe hyperglycemia ([@bib5; @bib50]) ([Table 2](#tbl2){ref-type="table"}). They have normal exocrine function, lack beta cells, and have fewer alpha and pancreatic polypeptide cells ([@bib50]). The patients with homozygous null mutations in *NKX2-2* also have severe developmental delay, which affects both motor and intellectual function as well as more specific features, such as hypotonia, cortical blindness, impaired visual tracking, and hearing impairment. These are consistent with the severe neurological features seen in the *Nkx2-2* knockout mouse ([Table 2](#tbl2){ref-type="table"}) and *Nkx2-2* being essential for hindbrain development, ventral neuronal patterning, and oligodendrocyte differentiation ([@bib5; @bib36]).

Homozygous Mutations in *MNX1* Cause Neonatal Diabetes {#sec2.2}
------------------------------------------------------

Two probands have homozygous missense mutations in *MNX1* (previously described as *HLXB9*). The p.F248L and p.F272L missense mutations are highly likely to be pathogenic, as they cosegregate with neonatal diabetes ([Figure 1](#fig1){ref-type="fig"}B), affect highly conserved residues within the homeodomain ([Table 2](#tbl2){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}C), are not listed in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project, and in silico analysis predicted the mutations to be disease causing. Our results are in line with the recently published paper by [@bib4], who independently found the same *MNX1* p.F272L mutation in proband 2. Both probands in our study had severe intrauterine growth retardation and were diagnosed with diabetes in infancy without evidence of exocrine pancreatic dysfunction. This is similar to the *Mnx1* null mice that are born smaller than their wild-type littermates and have small islets and reduced numbers of beta cells and normal exocrine function ([Table 2](#tbl2){ref-type="table"}) ([@bib15]). These mice also have dorsal lobe agenesis of the pancreas; it is not known if this is a feature of our two patients, as imaging and post mortem investigations were not performed. Proband 1 (but not proband 2) had marked extrapancreatic developmental features, including severe neurological complications and hypoplastic lungs (respiratory failure caused death at 10 months) ([Table 2](#tbl2){ref-type="table"}). In keeping with these observations, *Mnx1* null mice have aberrant motor neuron differentiation but are difficult to study as they die at birth due to respiratory paralysis, which probably results from failure in the development of the phrenic nerve ([@bib52]). The variability in phenotype between the two probands could be due to differences in the severity of their mutations, but further studies investigating the functional consequences of these missense mutations are required in order to explore this hypothesis.

Proband 1 also had sacral agenesis and a high imperforate anus, which are both cardinal features of Currarino syndrome (OMIM \#176450), resulting from heterozygous *MNX1* mutations ([@bib6; @bib37]). Mice homozygous for a null mutation do not have skeletal defects ([@bib15]). Proband 2 and his heterozygous relatives do not have features of Currarino syndrome. The highly variable phenotype is not unexpected, as around 50% of heterozygous carriers are clinically asymptomatic ([@bib21]). As diabetes is not a feature of Currarino syndrome, it seems likely that a single copy of *MNX1* is sufficient to maintain normal pancreatic development and glucose homeostasis, a hypothesis that is further supported by the observation that heterozygous mice have a normal pancreas ([@bib15]).

Known Causes of Neonatal Diabetes {#sec2.3}
---------------------------------

Homozygous mutations in five pancreatic transcription factor genes previously reported to cause PNDM were identified in seven probands. The phenotype of these patients is similar to that seen in mice with biallelic inactivation of these genes ([Table 3](#tbl3){ref-type="table"}). Our two patients with *GLIS3* mutations, the six previous cases ([@bib10; @bib43]), and the *Glis3* mouse knockout ([@bib55]) all have neonatal diabetes diagnosed in the first week of life and congenital hypothyroidism. We identified one patient with a homozygous *NEUROD1* mutation. Both this patient and a previously reported case from a nonconsanguineous pedigree ([@bib39]) have neonatal diabetes, neurodevelopmental delay, cerebellar hypoplasia, and hearing and visual impairment. The *Neurod1* null mouse also has neonatal diabetes and severe neurological defects, including impaired coordination and ataxia, cerebellar hypoplasia, sensorineural deafness, and retinal blindness ([@bib25; @bib27; @bib29; @bib30; @bib35]). The proband with a homozygous *RFX6* mutation was diagnosed with diabetes at 8 days and had duodenal atresia and gall bladder agenesis. This is consistent with the previous five cases and the *Rfx6* knockout mouse, which has neonatal diabetes and small bowel atresia ([@bib46]).

Two probands with homozygous *PDX1* (previously described as *IPF1*) missense mutations had isolated PNDM. In both man and mouse, the severity of the *PDX1* mutation determines the pancreatic phenotype. Pancreatic agenesis was seen in the mouse knockout ([@bib18]) and in patients with two copies of a severe mutation ([@bib11; @bib41; @bib48; @bib49; @bib54]). In mice, hypomorphic mutations are associated with diabetes without evidence of exocrine deficiency ([@bib34]); we and others have shown that patients with less-severe homozygous missense mutations have neonatal diabetes with normal or mildly impaired exocrine function ([@bib7; @bib31]).

An intronic *PTF1A* mutation (c.784 + 4A \> G) was identified in a proband with pancreatic agenesis. This mutation is predicted to result in an alternative splice donor site (Alamut Interactive Biosoftware, version 2.1) and the inclusion of an additional 4 bases in the mRNA, causing a frameshift and premature termination codon at residue 271. The pancreatic phenotype is similar to the three previously reported patients with nonsense or frameshift mutations and the *Ptf1a* null mouse ([@bib1; @bib22; @bib42]). Our patient has mild learning difficulties at 15 years old, which is in contrast to the other patients who had severe neurological features, causing death before 4 months of age. These patients and the knockout mouse had cerebellar aplasia. In a mouse model, reduced *Ptf1a* gene dosage results in pancreatic hypoplasia and glucose intolerance in a dose-dependent manner ([@bib13]). We hypothesize that the absence of cerebellar agenesis in this patient may reflect a reduced functional severity of the splicing mutation compared to previously reported null mutations.

The finding that mutations in *NKX2-2* and *MNX1* can cause neonatal diabetes takes the number of genes in which mutations are known to cause PNDM from 18 to 20, of which 10 encode pancreatic transcription factors. Unlike previous studies, which have identified mutations in humans because of similarities in phenotype with the null mouse, our systematic approach guided by areas of linkage has allowed us to screen all transcription factor genes independently of clinical features. Our results confirm that the consequence of inactivation of pancreatic transcription factor genes in humans is similar to the phenotype observed in knockout mice. This is in contrast to heterozygous loss-of-function mutations where differences in phenotype have been observed. For example, monoallelic mutations in *GATA6* or *HNF1B* cause pancreatic agenesis with congenital heart defects or renal cysts with diabetes, respectively, while mice heterozygous for a null mutation in *Gata6* or *Hnf1b* show no obvious phenotype ([@bib3; @bib16; @bib24; @bib28]).

There are some limitations to our study. The minimum prevalence of transcription factor mutations in our cohort of patients with consanguineous PNDM was 7.5%, but the true prevalence may be slightly higher since heterozygous or compound heterozygous mutations would have been missed as a result of the study design. However, as all of the patients were known to be consanguineous, the prior probability is that they have recessively inherited disease due to a homozygous mutation. While the identification of patients with homozygous inactivating mutations in pancreatic transcription factor genes has confirmed their role in human organogenesis, these findings can only provide limited information on pancreatic development, as detailed physiological studies in man are not always possible. This is especially true for the patients within our cohort with *NKX2*-2 and *MNX1* mutations that are all currently under 13 years of age and, for those with *NKX2*-2 mutations, have severe developmental delay, which means that in-depth studies on pancreatic and neurological function are not possible.

In conclusion, we have shown that mutations in *NKX2*-2 and *MNX1* cause neonatal diabetes. This confirms a key role for NKX2-2 and MNX1 in human pancreatic development. Comparisons of phenotypes observed in humans and mice with inactivation of transcription factor genes supports common steps critical for pancreatic development. This study validates the use of knockout mice for understanding beta cell development in humans.

Experimental Procedures {#sec3}
=======================

Cohort {#sec3.1}
------

We recruited 147 patients from consanguineous pedigrees (parents of the proband were second cousins or more closely related) who were diagnosed with permanent diabetes before 6 months of age or were diagnosed with permanent diabetes before 9 months and had any additional clinical features that made a diagnosis of type 1 diabetes less likely. Informed consent was obtained from all participants or their parents, and institutional review board approval was received for this study.

Exclusion of Nontranscription Factor Mutations in PNDM {#sec3.2}
------------------------------------------------------

To detect mutations in non-transcription factor genes that cause PNDM, we used Sanger sequencing (*ABCC8*, *KCNJ11*, *INS*) in all patients, followed by homozygosity mapping with sequencing of known genes (*EIF2AK3*, *IER3IP1*, *GCK*, *SLC19A2*, and *SLC2A2*) within homozygous regions \>3 Mb.

Detecting Mutations of Pancreatic Transcription Factor Genes {#sec3.3}
------------------------------------------------------------

From published literature, we identified 29 transcription factor genes crucial for murine pancreatic development ([@bib44; @bib56]) ([Table 1](#tbl1){ref-type="table"}). We identified homozygous regions through genome-wide single nucleotide polymorphism (SNP) genotyping and used Sanger sequencing to detect mutations within homozygous regions encompassing these genes.

Genome-wide SNP Analysis to Localize Etiological Genes by Linkage {#sec3.4}
-----------------------------------------------------------------

Genotyping was undertaken on the Affymetrix 10K, 500K, or v6.0 SNP chips by Medical Solutions, ALMAC Diagnostics, or AROS Applied Biotechnology. Processing of genomic DNA was performed as per the Affymetrix protocol, and in-house Perl scripts were developed to identify regions of significant homozygosity (\>3 Mb) as previously described ([@bib12]).

Sequencing of Pancreatic Transcription Factor Genes {#sec3.5}
---------------------------------------------------

When a large homozygous region encompassing one of the pancreatic transcription factor genes was identified, the coding regions and intron and exon boundaries of the gene were sequenced ([Table 1](#tbl1){ref-type="table"}, [Figure S1](#app2){ref-type="sec"}, and [Tables S2](#app2){ref-type="sec"} and [S3](#app2){ref-type="sec"}). Details of PCR primers and sequencing conditions are available on request. Pathogenicity was assessed on the basis of the characteristics of the mutation, the conservation of the affected amino acid, the absence from variant databases (accessed using Alamut v.2 Interactive Biosoftware), and cosegregation within families.

Patient Phenotype Assessment {#sec3.6}
----------------------------

For patients with homozygous mutations, their phenotype (both pancreatic and extrapancreatic) was compared with the phenotype of the knockout mouse for the same gene.

Supplemental Information {#app2}
========================
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![*NKX2-2* and *MNX1* Mutations in Four Families with Neonatal Diabetes\
(A) Partial pedigrees of two families in which *NKX2-2* mutations were identified. Below each pedigree is an electropherogram depicting the homozygous mutation identified in each proband. N/A, not available.\
(B) Partial pedigrees of two families with *MNX1* mutations. Below each pedigree is an electropherogram depicting the homozygous mutation identified in each proband.\
(C) The highly conserved sequence of the homeobox domain within MNX1 is provided for various species. An arrow points to the residues found to be mutated in the two probands with permanent neonatal diabetes. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

###### 

Pancreatic Transcription Factor Gene Analysis in Patients with Neonatal Diabetes, Related to [Tables S1](#app2){ref-type="sec"} and [S2](#app2){ref-type="sec"}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene            Diabetes Phenotype of the Null Mouse   Number of Homozygous Regions in 37 Patients   Mutations Identified in PNDM Patients   Homozygous Region Coordinates     Homozygous Mutations Identified   Reference(s) in which Patient Was Previously Reported
  --------------- -------------------------------------- --------------------------------------------- --------------------------------------- --------------------------------- --------------------------------- -------------------------------------------------------
  *FOXA1*         --                                     2                                             0                                       --                                --                                --

  *FOXA2*         embryonic lethal                       1                                             0                                       --                                --                                --

  *GATA4*         embryonic lethal                       2                                             0                                       --                                --                                --

  *GATA6*         embryonic lethal                       3                                             0                                       --                                --                                --

  *GLIS3*         neonatal diabetes                      4                                             2                                       chr9: 36,587--4,187,290\          p.? (c.1.−?\_388 + ?del)\         [@bib10]
                                                                                                                                               chr9: 39,094,547--46,744,084      p.G311fs (c.932 delG)             

  *HES1*          pancreatic hypoplasia                  2                                             0                                       --                                --                                --

  *HHEX*          pancreatic hypoplasia                  1                                             0                                       --                                --                                --

  *HNF1B*         embryonic lethal                       1                                             0                                       --                                --                                --

  *INSM1*         neonatal lethal                        2                                             0                                       --                                --                                --

  *ISL1*          pancreatic hypoplasia                  2                                             0                                       --                                --                                --

  *MAFA*          diabetes at 8--12 weeks                0                                             0                                       --                                --                                --

  *MAFB*          neonatal lethal                        4                                             0                                       --                                --                                --

  *MNX1*          pancreatic hypoplasia                  10                                            2                                       chr7: 147,339,570--158,659,419\   p.F248L (c.744C \> G)\            [@bib4]
                                                                                                                                               chr7: 155,022,291--158,811,981    p.F272L (c.816C \> A)             

  *NEUROD1*       neonatal diabetes                      3                                             1                                       --                                p.D122fs (c.364 dupG)             [@bib39]

  *NEUROG3*       neonatal diabetes                      1                                             0                                       --                                --                                --

  *NKX2.2*        neonatal diabetes                      2                                             2                                       chr20: 4,435,760--60,974,283\     p.P119fs (c.356 del)\             --
                                                                                                                                               chr20: 19,494,958--32,325,488     p.R129X (c.385C \> T)             

  *NKX3.2*                                               4                                             0                                       --                                --                                --

  *NKX6.1*        reduced insulin secretion              2                                             0                                       --                                --                                --

  *NKX6.2*                                               4                                             0                                       --                                --                                --

  *ONECUT1*       adult-onset diabetes                   3                                             0                                       --                                --                                --

  *PAX4*          neonatal diabetes                      1                                             0                                       --                                --                                --

  *PAX6*          neonatal lethal                        0                                             0                                       --                                --                                --

  *PDX1*          pancreatic agenesis                    4                                             2                                       chr13: 27,258,487--42,966,967\    p.A152G (c.455C \> G)\            [@bib7]
                                                                                                                                               chr13: 21,702,312--43,640426      p.R176Q (c.527G \> A)             

  *PTF1A*         pancreatic agenesis                    8                                             1                                       chr10: 14,877,485--49,578,351     p.? (c.784 + 4A \> G)             [@bib24]

  *RBPJ*          embryonic lethal                       2                                             0                                       --                                --                                --

  *RBPJL*                                                4                                             0                                       --                                --                                --

  *RFX6*          neonatal diabetes                      5                                             1                                       chr6: 109,613,154--144,987,523    p.S217P (c.649T \> C)             [@bib46]

  *SOX17*         embryonic lethal                       1                                             0                                       --                                --                                --

  *SOX9*          embryonic lethal                       6                                             0                                       --                                --                                --

                                                                                                                                                                                                                   

  **Total: 29**   --                                     **Total: 84**                                 **Total: 11**                           --                                --                                --
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Transcription factor genes important for murine pancreatic development and the resulting diabetes phenotype in null mice. Genome-wide SNP typing identified 84 homozygous regions encompassing a transcription factor gene in 30 patients with permanent neonatal diabetes. Using Sanger sequencing, 11 mutations were detected in 7 of these genes.

###### 

Clinical Characteristics of Patients with Homozygous *NKX2-2* or *MNX1* Mutations and Comparisons with Mouse Model, Related to [Table S3](#app2){ref-type="sec"}

  NKX2-2                                   Homozygous Null Mouse[∗](#tblfn1){ref-type="table-fn"}                                   Humans                                                                                                                                                                                                                                                 
  ---------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Gender                                   --                                                                                       female                                                                                                                                                       male                                                                                      female
  Current age (years)                      --                                                                                       5.5                                                                                                                                                          1.5                                                                                       13
  Birth weight (gestation)                 --                                                                                       1.36 kg (35 weeks)                                                                                                                                           1.68 kg (40 weeks)                                                                        1.22 kg (37 weeks)
  Birth weight (SDS)                       not distinguishable from wild-type littermates at birth                                  −2.8                                                                                                                                                         −3.64                                                                                     −4.52
                                                                                                                                                                                                                                                                                                                                                                                           
  **Pancreatic Features**                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                           
  Age diagnosis (days)                     2                                                                                        2                                                                                                                                                            2                                                                                         7
  Glucose at presentation (mmol/l)         23 (4.5 wild-type littermates)                                                           18                                                                                                                                                           not available                                                                             67
  Current insulin requirement (U/kg/day)   --                                                                                       0\. 57                                                                                                                                                       0.60                                                                                      1.2
  Current HbA1c (%) (mmol/mol)             --                                                                                       9% (75)                                                                                                                                                      7.9% (63)                                                                                 9.5%--12% (80--108)
  Evidence of exocrine insufficiency       no                                                                                       no                                                                                                                                                           no                                                                                        no
                                                                                                                                                                                                                                                                                                                                                                                           
  **Extrapancreatic Features**                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                           
  CNS                                      retarded oligodendrocyte differentiation and absence of hindbrain serotonergic neurons   severe developmental delay (unable to stand or talk at 5 years of age), hypotonia, cortical blindness, thin corpus callosum and generalized gliosis on MRI   severe developmental delay (motor function is that of a 5 month old at 9 months of age)   moderate developmental delay (walks with assistance at 11 years of age), hypotonia, inability to fix gaze and follow, bilateral hearing impairment
  Growth                                   growth retarded                                                                          short stature (−3 SDS)                                                                                                                                       --                                                                                        short stature (−2.2 SDS)
  Additional features                      none reported                                                                            swallowing difficulties, severe constipation                                                                                                                 constipation                                                                              none reported

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MNX1                                   Homozygous Null Mouse[∗](#tblfn1){ref-type="table-fn"}             Humans                                                                                                                                                               
  -------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Gender                                 --                                                                 male                                                                                                                                                                 female

  Current Age                            --                                                                 deceased at an age of 10 months                                                                                                                                      3 years

  Birth weight (gestation)               IUGR                                                               2.23 kg (40 weeks)                                                                                                                                                   1.90 kg (38 weeks)

  Birth weight (SDS)                     --                                                                 −2.54                                                                                                                                                                −3.09

                                                                                                                                                                                                                                                                                 

  **Pancreatic Features**                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                 

  Age at diagnosis of diabetes (weeks)   dorsal lobe agenesis, small islets, reduced number of beta cells   30                                                                                                                                                                   1

  Glucose at presentation (mmol/l)       --                                                                 12.1                                                                                                                                                                 35

  Insulin requirement                    --                                                                 0.3 U/kg/day                                                                                                                                                         0.8 U/kg/day

  HbA1c %\                               --                                                                 6.6% (49)                                                                                                                                                            7.8% (62)
  (mmol/mol)                                                                                                                                                                                                                                                                     

  Evidence of exocrine insufficiency     no                                                                 no                                                                                                                                                                   no

                                                                                                                                                                                                                                                                                 

  **Extrapancreatic Features**                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                 

  CNS                                    aberrant motor neuron differentiation, absent phrenic nerve        severe developmental delay, poor suck and swallow, neurogenic bladder, flexion deformities of legs, MRI scan of brain demonstrated generalized reduction in myelin   none reported

  Muscular/skeletal                      --                                                                 short stature (\<3^rd^ percentile)                                                                                                                                   normal stature (59^th^ percentile)

  Lung                                   pulmonary paralysis and lung atelectasis (neonatal lethal)         hypoplastic lungs requiring CPAP                                                                                                                                     none reported

  Additional features                    not reported                                                       rocker bottom feet, poorly developed renal cortex and medulla, sacral agenesis, high imperforate anus                                                                failure to thrive (current weight 11.7kg, \<5^th^ percentile)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse data reported in [@bib2; @bib5; @bib15; @bib36; @bib50], and [@bib52]. SDS, SD scores; IUGR, intrauterine growth retardation; CPAP, continuous positive airway pressure.

###### 

A Comparison of the Phenotype Observed in the Patients with Homozygous Mutations in Known Pancreatic Transcription Factors to the Phenotype Observed in Homozygous Inactivation in Mice

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         Mutation                Patient                                                                     Mouse                                                                                            References                                                                                                                                                                                 
  ------------ ----------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------
  *GLIS3*      c.1.−?\_388 + ?del^1^   neonatal diabetes                                                           renal cystic dysplasia, congenital hypothyroidism, hepatic fibrosis                              null: neonatal diabetes                       null: neonatal lethality, polycystic kidney disease, congenital hypothyroidism                                                               [@bib55]

  c.932 delG   neonatal diabetes       multiple small renal cysts, congenital hypothyroidism, osteopenia, anemia                                                                                                                                                                                                                                                                                               

  *NEUROD1*    c.364 dupG^2^           neonatal diabetes                                                           learning difficulties, severe cerebellar hypoplasia, sensorineural deafness, retinal dystrophy   null: neonatal diabetes                       null: cerebellar hypoplasia, impaired coordination and ataxia, impaired hearing and balance, retinal degeneration, blindness, and seizures   [@bib20; @bib25; @bib29; @bib30]

  *PDX1*       p.A152G^3^              neonatal diabetes                                                           none reported                                                                                    null: pancreatic agenesis\                    null: abnormal duodenum and stomach morphology\                                                                                              [@bib18; @bib33; @bib34; @bib48]
                                                                                                                                                                                                                    hypomorphic mutation: neonatal diabetes       hypomorphic mutation: none reported                                                                                                          

  p.R176Q^3^   neonatal diabetes       none reported                                                                                                                                                                                                                                                                                                                                                           

  *PTF1A*      c.784 + 4A \> G^4^      pancreatic agenesis                                                         none reported                                                                                    null: pancreatic agenesis\                    null: cerebellar hypoplasia\                                                                                                                 [@bib13; @bib17; @bib19; @bib22; @bib42]
                                                                                                                                                                                                                    hypomorphic mutation: pancreatic hypoplasia   hypomorphic mutation: cerebellar hypoplasia                                                                                                  

  *RFX6*       p.S217P^5^              neonatal diabetes                                                           duodenal atresia,\                                                                               null: neonatal diabetes                       null: small bowel atresia                                                                                                                    [@bib46]
                                                                                                                   gall bladder agenesis                                                                                                                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some patients have been reported previously by [@bib10; @bib39; @bib7; @bib24], and [@bib46].
